tradingkey.logo

Teva Reports Ninth Consecutive Quarter Of Growth In Q1 2025 With Key Innovative Medicines Growing ~40% 2025 Profit Outlook Improved

ReutersMay 7, 2025 11:09 AM

- Teva Pharmaceutical Industries Ltd TEVA.TA:

  • TEVA REPORTS NINTH CONSECUTIVE QUARTER OF GROWTH IN Q1 2025 WITH KEY INNOVATIVE MEDICINES GROWING ~40%; 2025 PROFIT OUTLOOK IMPROVED

  • TEVA: ON TRACK FOR 30% OPERATING PROFIT MARGIN BY 2027 IN LINE WITH OUR PIVOT TO GROWTH STRATEGY

  • TEVA: CURRENT, CONFIRMED U.S. TARIFFS EXPECTED TO HAVE IMMATERIAL IMPACT; ABSORBED IN UPDATED 2025 NON-GAAP OUTLOOK

  • TEVA: ANNOUNCED ABOUT $700 MILLION NET SAVINGS BY 2027

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI